Allogene spells out its interest in Cellectis
As Allogene moves to follow Autolus onto the public markets, its IPO document could give hope that Cellectis’s allogeneic assets will at long last make meaningful…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.